Background and Purpose-The level of total homocysteine (tHcy) that confers a risk of ischemic stroke is unsettled, and no prospective cohort studies have included sufficient elderly minority subjects. We investigated the association between mild to moderate fasting tHcy level and the incidence of ischemic stroke, myocardial infarction, and vascular death in a multiethnic prospective study. Methods-A population-based cohort was followed for vascular events (stroke, myocardial infarction, and vascular death).
A n independent and dose-related relationship between elevated total homocysteine (tHcy) and atherosclerotic diseases has been demonstrated by multiple studies. 12, 3 There are gaps, however, in our knowledge of the association between tHcy and stroke. The association has been less apparent among prospective cohorts compared with casecontrol and cross-sectional studies, and the level of tHcy that confers a risk of ischemic stroke is unsettled. 4 -11 Few studies have adequately controlled for B 12 deficiency, which is associated with elevated levels of tHcy. 1213 Moreover, the studies on tHcy as a risk factor for stroke have been mostly limited to white populations, 4 -9 and mostly among men. [7] [8] [9] Blacks have a greater risk of stroke and a greater prevalence of many cardiovascular risk factors. 14 -15 Little is known about the effects of tHcy among blacks and the United States' rapidly growing Hispanic population. The aim of our study was to evaluate the effect of tHcy on vascular outcomes, including stroke, myocardial infarction (MI), and vascular death, in a prospective cohort with a substantial representation of women and minorities after adjusting for vitamin B 12 deficiency and known vascular risk factors.
Methods
The NOrthern MAnhattan Study (NOMAS) is a population-based study designed to evaluate the incidence of stroke and identify novel risk factors in a multiethnic urban community. The race-ethnic distribution is Ϸ63% Hispanic, 20% black, and 15% white.
Selection of Prospective Cohort
A total of 3298 subjects were recruited and enrolled between 1993 and 2001 into a prospective cohort study. Community participants were eligible if they (1) had never been diagnosed with a stroke, (2) were Ն40 years of age, and (3) resided for at least 3 months in a household with a telephone in Northern Manhattan. Subjects were identified by random digit dialing using dual-frame sampling to identify both published and unpublished telephone numbers. Methods of subject recruitment have been described in prior publications. 16 Research protocols were approved by the Columbia University Medical Center Institutional Review Board.
Baseline Evaluation
Subjects were recruited from the telephone sample for an in-person baseline assessment. The overall response rate was 68%. Baseline data were collected through interviews of the community subjects by trained bilingual research assistants using standardized data collection instruments, review of the medical records, physical and neurological examination by study physicians, and fasting blood specimens for tHcy, glucose, lipid, and methylmalonic acid (MMA) measurements.
Race-ethnicity was based on self-identification as defined in prior publications. 16 Standardized questions were adapted from the Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance System regarding vascular risk factors as defined previously. 17 
Laboratory Assessments
Baseline blood samples were drawn into serum tubes and spun within 1 hour at 3000g at 4°C for 20 minutes and frozen at Ϫ70°C, which has been shown to be stable for tHcy assays. 18 Fasting serum tHcy and MMA were measured using methods that have been licensed for commercial use. 19 The Core Laboratory of the Irving Center for Clinical Research also measured serum B 12 and folate levels in a subsample of the cohort using SimulTRAC-S radioimmunoassay kits for those recruited after 1998. Lipids were measured as previously described. 17 Vitamin B 12 deficiency was defined as a MMA level Ͼ271 nmol/L, and renal insufficiency was defined as a creatinine level Ͼ1.5 mg/dL. Mean MMA was 214 nmol/L, and 25 subjects (0.9% of the cohort) had MMA Ͼ1000 nmol/L.
Annual Prospective Follow-Up
All subjects were prospectively followed annually by telephone. Subjects were interviewed to determine changes in vital status, detect neurological and cardiac symptoms and events, and review any interval hospitalizations. Our phone assessment served as a screen for events. The telephone interview simple stroke question ("Since your last visit have you been diagnosed with a stroke?") had a sensitivity of 92% and specificity of 95%. Moreover, a 10% random sample of the cohort was followed annually in-person for 5 years to evaluate for any telephone false-negatives and evaluate for serial change in baseline conditions.
Any subject who screened positive by telephone was scheduled for an in-person assessment. All affirmative responses to neurological symptoms and conditions required a review and examination by the study neurologist. Hospital surveillance of admission and discharge International Classification of Diseases, Ninth Revision (ICD-9) codes provided data on mortality and morbidity that may not have been captured during annual telephone follow-up.
Outcome Classifications (Stroke, MI, and Death)
Stroke was defined by the first symptomatic occurrence of any type of stroke including intracerebral hemorrhage, subarachnoid hemorrhage, and cerebral infarction. Stroke was defined by the World Health Organization criteria as "rapidly developing clinical signs of focal (at times global) disturbance of cerebral function, lasting more than 24 hours or leading to death with no apparent cause other than that of vascular origin." Stroke subjects had a battery of standard diagnostic tests including brain imaging, used to confirm ischemic stroke subtype. Medical records of all hospitalizations were reviewed to verify the details of any suspected events. Two neurologists classified the strokes independently after review of all of the data and the principal investigator adjudicated any disagreements.
MI was defined by criteria adapted from the Cardiac Arrhythmia Suppression Trial 20 For subjects who died, the date of death was recorded along with cause of death. Deaths were classified as vascular or nonvascular based on information obtained from the family, medical records, and death certificate. Causes of vascular death included stroke, MI, heart failure, pulmonary embolus, cardiac arrhythmia, and other vascular causes. Nonvascular causes of death included accident, cancer, pulmonary (pneumonia, chronic obstructive pulmonary disease, etc), and other nonvascular causes.
Statistical Analyses
The prevalence of categorized sociodemographic factors, conventional risk factors, and potential confounders were calculated, and the mean differences of plasma tHcy levels were evaluated. Age, sex, race, and education were considered as sociodemographic factors. Hypertension, diabetes, any cardiac disease, high-density lipoprotein Ͻ40 mg/dL, cigarette smoking, and mild to moderate alcohol consumption were included as conventional vascular risk factors. We included baseline vitamin B 12 deficiency and renal insufficiency as other covariates.
Natural log transformed values of tHcy were used in the analyses. For each outcome, we estimated the log hazard ratio (HR) as an unspecified function of log tHcy by fitting a general spline term within the Cox regression model. S-plus (Insightful Corporation) was used to fit semiparametric Cox model with spline. From the estimated relationship between log tHcy and log HR for ischemic stroke, the log tHcy value 2.3 corresponded to the point when the HRϭ1, and 2.7 corresponded to the point when the HRϭ1.3. Based on these inverse predictions, log tHcy levels were trichotomized:
Cox proportional regression models were used to examine the association between the log tHcy and the incidence of each outcome during follow-up, before and after adjusting for other possible confounding factors including B 12 deficiency and renal insufficiency. Time to the first event among combined vascular events was the failure time, and the failure time is censored either at the death or the last follow-up. The proportional hazard assumption was examined. Interactions were evaluated between log tHcy and sociodemographic and conventional risk factors. In supplementary analyses, B 12 and folate were adjusted as continuous variables. Stratified analyses were conducted by race/ethnicity and sex for combined vascular event. All statistical analyses were performed with the use of SAS software (SAS Institute).
Results
The cohort for this report consisted of 2939 subjects (89%) for whom we had tHcy and MMA measurements, and the baseline characteristics (Table 1) were similar to the original total cohort. The mean age was 68.9Ϯ10.2 years (range, 40 to 107). Women outnumbered men and the majority of the population were Hispanics, followed by black non-Hispanics, and white non-Hispanics. Vitamin B 12 deficiency, estimated using MMA, was observed among 489 (16.6%) of the population, and renal insufficiency was found among 92 (3.4%) subjects. In a sample, the correlations between B 12 and MMA were excellent. The ␥ statistic comparing concordance pairs to discordance pairs was 0.82Ϯ0.05, verifying that MMA was an excellent proxy for vitamin B 12 deficiency.
The mean baseline tHcy was 10.2Ϯ5.0 mol/L, median 9.2, and interquartile range 7.5 to 11.5. A level of 10 mol/L was the 61st percentile, and a level of 15 mol/L was Ϸ90th percentile. The distribution was skewed and tHcy levels were log transformed. The mean tHcy level was significantly greater among those Ͼ65 years of age, men, and in blacks more than in whites and Hispanics (Table 1) . Mean tHcy was also greater among those with hypertension, any cardiac disease, high-density lipoprotein cholesterol Ͻ40 mg/dL, cigarette smoking, B 12 deficiency, and renal insufficiency. Mean tHcy was less among mild to moderate drinkers.
The mean and median follow-up of the cohort was 5 and 4 years, respectively. Only 1 subject was lost to follow-up and the average annual contact rate was 95%. We detected 125 strokes, 101 MIs, 132 vascular deaths, and 251 nonvascular deaths during this period. Of the 125 subjects with stroke, 103 (82%) were classified as infarcts, 13 (10%) as intracerebral hemorrhage, 2 (2%) as subarachnoid hemorrhage, and 7 (6%) are pending.
The estimated log HR as a function of the baseline log tHcy and its pointwise 95% CIs for various outcomes are graphically displayed in the Figure. Slopes were similar for ischemic stroke and MI. The slope of the curves was greater for vascular death than for nonvascular death and ischemic stroke.
The age-adjusted incidence rate for tHcy Ն15 mol/L was 13.61 per 1000 person-years for ischemic stroke and 41.16 per 1000 person-years for combined vascular events (Table  2 ). In the Cox regression model, tHcy Ն15 mol/L, compared with reference levels Ͻ10 mol/L, was a significant and independent predictor of the risk of ischemic stroke with HRs Ϸ2.0 after adjusting for sociodemographic, conventional risk factors, and vitamin B 12 deficiency (Table 3 ). The HR for tHcy Ն15 mol/L remained a significant predictor of ischemic stroke even after adjusting for renal insufficiency. Total Hcy 10 to 15 mol/L was not significantly predictive of ischemic stroke. In a subgroup of 1725 subjects on whom we had serum measurements of vitamin B 12 and folate levels, the effect of tHcy on ischemic stroke persisted after adjusting for B 12 and folate levels. The HR for ischemic stroke at levels of 
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tHcy 10 to 15 mol/L and Ն15 mol/L were 1.33 (0.89 to 1.97) and 2.06 (1.25 to 3.39), respectively. Elevated tHcy at both levels (10 to 15mol/L and Ն15 mol/L) was a strong and significant predictor for vascular death. HRs were 6.0 for tHcy Ն15 mol/L in the adjusted model. More moderate levels of tHcy 10 to 15 mol/L remained a significant predictor of vascular death with HRs Ϸ2.3. Elevated tHcy levels were also an independent and significant predictor for the combined vascular events and nonvascular death, but the relationship for nonvascular death attenuated to an HR 2.0 in the adjusted model for tHcy Ն15mol/L and 1.3 for 10 to 15 mol/L (Table 3) .
In the stratified analysis by race-ethnicity, whites had the greatest adjusted HRs for ischemic stroke and combined vascular events due to elevated tHcy levels, followed by Hispanics (Table 4) . tHcy was not detected as a risk factor for ischemic stroke or combined vascular events among blacks. A significant interaction by race-ethnicity was detected Relationship between fasting total homocysteine and risk of vascular events. The estimated log of the hazard ratio (HR) is plotted as a function of the log of total baseline homocysteine value with the 95% confidence margins shown with the dashed lines. HR 1.0 is equivalent to log hazard of 0; HR 1.3 indicates log HR of 0.26. tHcy of 10 mol/L indicates log tHcy of 2.3; tHcy 15 mol/L, log tHcy of 2.7 (PϽ0.05). No interactions were detected between tHcy and age or sex, nor among those with or without hypertension, any cardiac disease, diabetes, or cigarette smoking.
Discussion
Our prospective cohort study confirms that elevated tHcy is a risk factor for ischemic stroke and combined vascular events; however, the risk is differential across outcome events and varies by race-ethnicity. For ischemic stroke, the HR for tHcy levels Ͻ10 mol/L were Ͻ1; the hazard increased only slightly for 10 to 15 mol/L, and almost doubled for Ն15 mol/L. In our older-aged multiethnic cohort, few MIs occurred among persons with baseline tHcy Ն15 mol/L. HRs were particularly elevated for vascular death followed by nonvascular deaths. For combined vascular events, tHcy was a strong and independent risk factor even at mild to moderate elevations (10 to 15 mol/L).
There were no significant differences in the associations between tHcy and vascular outcomes by age or sex, but we did observe a significant difference by race/ethnicity. tHcy was a stronger predictor for ischemic stroke and combined vascular events among whites. Effects among Hispanics were less than whites, but still significantly predictive of vascular outcomes. Despite the greater baseline tHcy levels among blacks, tHcy was weaker and a nonsignificant predictor of stroke or vascular events. Blacks have been found to have greater stroke incidence, and a greater proportion of strokes attributed to hypertension and diabetes. 22, 23 This could suggest that initiatives aimed at managing hypertension and diabetes may work better than reducing tHcy for stroke prevention among blacks.
Total Hcy is significantly elevated in the patients with renal failure even when folate and B 12 are replete. 24 In our cohort, we found an independent effect of tHcy after adjusting for renal insufficiency and B 12 and folate deficiency. In a subgroup analysis among 1725 subjects, the effect of tHcy remained significant after adjustment for conventional serum B 12 and folic acid levels. This implies that an association exists between tHcy and vascular outcomes even after adjusting for vitamin deficiencies and renal insufficiency.
We evaluated the effect of folic acid fortification that was mandated by the Food and Drug Administration (FDA) and initiated in January 1998. In our cohort, we observed a significant decrease in the tHcy levels after 1998. The mean tHcy level among those enrolled before 1998 was 11.1Ϯ4.6 mol/L, whereas it decreased to 9.6Ϯ5.2 mol/L among those enrolled after 1998. Despite this general reduction in tHcy, we observed a similar HR for tHcy among those enrolled before or after 1998.
Another interesting finding was the strong relationship between tHcy and nonvascular mortality. Similar findings have been reported in other studies. 25, 26 In our cohort, the association between vascular death and tHcy was consistent and did not attenuate in the adjusted models. Unlike vascular death, the association between nonvascular death and tHcy diminished markedly on adjusting for sociodemographic, Reference group indicates total fasting homocysteine Ͻ10 mol/L. *Models indicates (1) homocysteine only. (2) indicates (1)ϩage, sex, race-ethnicity, and education; (3), (2)ϩhyper-tension, diabetes, any cardiac disease, HDL Ͻ40 mg/dl, alcohol consumption, and cigarette smoking; (4), (3)ϩrenal insufficiency (creatinine Ͼ1.5 mg/dl) and B 12 deficiency (MMA Ͼ271 nmol/L).
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conventional risk factors, vitamin B 12 deficiency, and renal insufficiency. This could suggest that these factors partially explain the association between tHcy and nonvascular death. Cancer risk factors, such as cigarette smoking and a low intake of fruit and vegetables, are associated with elevated tHcy. 27 The residual effect could be because of the association between tHcy and cancer mortality. Our results regarding tHcy and stroke are consistent with the findings from other cohort studies. 5, 8 Both the British Regional Heart Study and the Framingham Study reported independent associations between tHcy levels and incidence of any stroke, but only for levels in the highest quartile (Ն15.4 mol/L and Ն14.24 mol/L, respectively). The relative risk in the British Regional Heart Study was 4.7 (1.1 to 20.0), and in the Framingham Study the odds ratio was 1.82 (1.14 to 2.91) in the highest quartile. The Rotterdam Study also reported a marked increase in the risk of any stroke beyond the upper quintile (18.6 mol/L), relative to the lowest quintile (Ͻ12.0 mol/L). In most studies, risks of vascular outcomes, including stroke, are increased for those with levels Ն15 mol/L as in our study, whereas the significance of intermediate elevations of tHcy from 10 to 15 mol/L are more controversial.
We acknowledge some limitations of our cohort study. We used total fasting plasma Hcy and not the methionine-loading test. This test is not practical in large epidemiological studies, and it may not be as sensitive to subclinical vitamin deficiencies. 28 We used a single baseline measure of tHcy to predict the outcomes and not repeated measures. This could bias estimates if there were significant intraindividual variability in the levels of tHcy. However, among 266 subjects on whom we had more than 2 measurements the intrastandard deviation for fasting tHcy was 1.88Ϯ2.86 mol/L, which was smaller than the overall standard deviation. Our cohort is a multiethnic, elderly, urban population with lower socioeconomic status and a lower number of white subjects. Such a cohort, although less representative of rural US populations, is relatively generalizable to the rapidly expanding inner city US populations.
Despite the well-documented evidence of the ease of reducing tHcy by vitamin supplementation with folic acid, vitamin B 6 , and vitamin B 12 , there is still a paucity of data documenting any vascular benefits. 29 Among survivors of ischemic stroke with borderline elevations of tHcy, high-dose vitamin therapy did not reduce the risk of recurrent stroke in the Vitamin Intervention Stroke Prevention Trial, perhaps because the reduction in the tHcy levels was very slight in the face of folate fortification of the grain supply. 30 Other randomized trials to assess the efficacy of reducing tHcy are ongoing for the prevention of stroke and cardiovascular risk. 31, 32 Our study supports the importance of these ongoing trials and calls for including sufficient elderly persons with tHcy Ͼ15 mol/L and a focus on all vascular outcomes, including ischemic stroke. 
